# DESCRIPTION

## STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

- disclose government sponsorship

## FIELD OF THE INVENTION

- relate to botulinum neurotoxin antibodies

## INTRODUCTION

- motivate botulism treatment

## SUMMARY

- disclose neutralizing antibodies
- describe antibody compositions
- outline methods of use

## DEFINITIONS

- define BoNT polypeptide
- define BoNT serotype and subtype
- define anti-BoNT antibody and neutralization
- define potency and LD50
- define high affinity and various abbreviations
- define bispecific antibodies
- describe antigen-binding site
- explain immunological binding properties
- define BoNT-neutralizing antibody
- describe epitope and neutralizing epitope
- define isolated and single chain Fv polypeptide

## DETAILED DESCRIPTION

- introduce botulinum neurotoxin and its subtypes
- describe neutralizing antibodies and their combinations
- discuss applications of neutralizing antibodies

### I. Potency of Botulinum Neurotoxin (BoNT)-Neutralizing Antibodies.

- describe potency of antitoxins

### II. Botulinum Neurotoxin (BoNT)-Neutralizing Antibodies.

- describe BoNT subtypes and cross-reactive antibodies
- provide sequences of variable heavy and light domains
- discuss epitopes bound by antibodies

### III. Preparation of BoNT Neutralizing Antibodies.

- describe recombinant expression of BoNT-neutralizing antibodies
- outline nucleic acid synthesis and cloning
- explain expression of anti-BoNT antibodies in various cells
- detail purification and folding of expressed antibodies
- describe transfection and expression in mammalian cells
- outline preparation of whole polyclonal or monoclonal antibodies
- summarize monoclonal antibody production using hybridomas

### IV. Modification of BoNT Neutralizing Antibodies.

- introduce display techniques for increasing antibody affinity
- describe chain shuffling for creating mutant scFv gene repertoires
- outline site-directed mutagenesis for increasing antibody affinity
- illustrate affinity maturation using yeast display
- create anti-BoNT (scFv′)2 homodimers
- prepare anti-BoNT (scFv)2, Fab, and (Fab′)2 molecules
- select neutralizing antibodies
- measure anti-BoNT antibody affinity for one or more BoNT subtypes
- describe purification of anti-BoNT antibody

### V. Humanized, Human Engineered or Human Antibody Production.

- define humanized antibodies
- describe chimeric antibodies
- explain CDR-grafted antibodies
- discuss human engineered antibodies
- introduce veneered antibodies
- describe de-humanizing CDR-grafted antibodies
- summarize human antibody production methods

### VI. Other Antibody Forms.

- introduce VHH and nanobodies
- describe camelid VHH and human VH domains
- discuss libraries of single VH domains
- introduce UniBodies
- introduce Affibodies
- reference prior art for affibody production

### VII. Assaying for Neutralizing Activity of Anti-BoNT Antibodies

- describe methods for assaying neutralizing activity

### VIII. Diagnostic Assays.

- describe diagnostic assays for botulism
- motivate biological sample selection
- outline immunoassay configurations
- describe non-competitive assay formats
- describe competitive assay formats
- discuss reduction of non-specific binding
- outline substrate options
- describe other assay formats
- discuss labeling of anti-BoNT antibodies

### IX. Compositions.

- describe BoNT-neutralizing antibody compositions
- motivate high-affinity antibody combinations
- list exemplary antibody combinations
- describe composition formats (e.g., single formulation, kit)
- discuss pharmaceutical composition administration methods
- describe non-aqueous carriers and antihydration agents
- outline composition preparation and dosage guidelines

## EXAMPLES

- provide illustrative examples

### Example 1

- describe materials and methods
- generate immune scFv yeast antibody library
- select and characterize lead BoNT/B and BoNT/A scFv antibodies
- construct and express yeast displayed BoNT/B domains
- map overlap of BoNT antibodies
- create light chain library
- construct and purify IgG
- measure solution phase affinity at equilibrium
- generate human yeast displayed scFv antibody libraries
- sort and characterize yeast displayed scFv
- determine BoNT/B subtype specificity
- determine BoNT/B functional domain recognized
- perform light chain shuffling and affinity maturation
- convert yeast displayed scFv to IgG and measure affinity

### Example 2

- introduce affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating
- describe methods and materials used
- construct light chain repertoire in YVH10 for light chain shuffling
- construct Fab libraries for affinity and specificity maturation of scFv lead clones
- perform yeast mating and selection of mutant clones from Fab libraries by FACS
- measure quantitative equilibrium binding constants by flow cytometry
- generate IgG from Fab genes
- measure IgG solution equilibrium binding constants by flow fluorimetry
- select antibodies for affinity maturation by light chain shuffling

### Example 3

- describe neutralization of BoNT/B in vivo by BoNT/B antibody combinations

### Example 4

- demonstrate BoNT/E neutralization in vivo

### Example 5

- describe materials and methods
- outline specificity and crossreactivity test
- describe measurement of yeast-displayed scFv affinity
- outline binding domain test
- describe construction of yeast-displayed BoNToxins fragments
- outline epitope sharing test and protein sequence alignment

